Tevogen Bio (NASDAQ:TVGN) Shares Up 0.9% – Still a Buy?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) rose 0.9% on Tuesday . The stock traded as high as $1.12 and last traded at $1.09. Approximately 181,605 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 5,081,068 shares. The stock had previously closed at $1.08.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Tevogen Bio in a report on Tuesday, March 11th.

Tevogen Bio Stock Up 0.9 %

The firm’s 50-day moving average price is $1.32 and its 200 day moving average price is $1.24.

Insider Buying and Selling at Tevogen Bio

In other news, insider Neal Flomenberg sold 70,384 shares of Tevogen Bio stock in a transaction on Monday, March 10th. The stock was sold at an average price of $1.09, for a total value of $76,718.56. Following the transaction, the insider now owns 3,898,828 shares in the company, valued at approximately $4,249,722.52. This trade represents a 1.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 406,510 shares of company stock worth $446,763 over the last three months. Corporate insiders own 56.60% of the company’s stock.

Institutional Trading of Tevogen Bio

Large investors have recently bought and sold shares of the business. HGC Investment Management Inc. acquired a new position in Tevogen Bio during the third quarter worth about $82,000. China Universal Asset Management Co. Ltd. acquired a new position in Tevogen Bio during the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. lifted its stake in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after purchasing an additional 16,695 shares during the last quarter. Geode Capital Management LLC boosted its position in Tevogen Bio by 31.2% in the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after buying an additional 107,566 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after buying an additional 12,847 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.